Drug intelligence / Profile preview

BI 3814916

Development stage: Phase 1
Lead developer: Boehringer
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

BI 3814916 is a biological drug candidate developed by Boehringer Ingelheim, currently in Phase 1 clinical development for the treatment of obesity and metabolic disorders. It acts as an agonist of the Growth Differentiation Factor 15 (GDF15) pathway. GDF15 is a stress-responsive cytokine that binds specifically to the GDNF family receptor alpha-like (GFRAL) in the hindbrain. Activation of GFRAL signaling suppresses appetite and reduces food intake, leading to weight loss. BI 3814916 is designed to leverage this mechanism to provide a therapeutic option for weight management, potentially as a monotherapy or in combination with other metabolic agents like GLP-1 receptor agonists.

Targets

GFRAL (Glial-derived neurotrophic factor family receptor alpha-like/ret receptor complex)

Beyond the preview

Go deeper on BI 3814916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3814916.

Explore the full profile